Amarin Corp Plc (AMRN)

[ralphey]

2. Reauthorization

a. Vascepa will be approved based on both of the following criteria:

1) Used for cardiovascular risk reduction
-AND-
2) Documentation of positive clinical response to therapy
-AND-
3) Patient is on an appropriate low-fat diet and exercise regimen
-AND-
4) Patient is receiving maximally tolerated statin therapy
-AND-
5) Prescribed by or in consultation with one of the following:
a) Cardiologist
b) Endocrinologist
c) Lipid specialist

5.) This is hilarious so I as a FAMILY MD have been prescribing Vascepa for probably 8 years - sent letter to all my local cardiologist several times - who still think it s just fish oil and tell my patients as much and UHC thinks I am not qualified to prescribe the med !

2.) DOcumentation of clinical response ? The clinical response is reduction of coronary events so if they have a coronary event they dont get the med ??

Eclipsing Family DOcs will cut into the market significantly especially on the diabetic + two risk factor equation most of those patients are being treated by family docs - AMRN needs to fight this